WEE1 inhibitors synergise with mRNA translation defects via activation of the kinase GCN2
Jordan Wilson, Jiayi Zhu, Vanesa Vinciauskaite, Eloise G. Lloyd, Simon C.C. Lam, Alexandra Hart, Chen Gang Goh, Fadia Bou-Dagher, Hlib Razumkov, Lena Kobel, Zacharias Kontarakis, John Fielden, Moritz F. Schlapansky, Joanna I. Loizou, Andreas Villunger, , Stephen P. Jackson
This study shows WEE1 inhibitors work better with mRNA translation defects by activating GCN2, and suggests ways to reduce off-target effects.
Nature Communications · Oct 9, 2025Peer-reviewedCancer Biology